Pacira expects that gap to narrow as it laps the prior-year impact. Pacira expects revenue from that arrangement to begin in 2027 and plans to provide updates on additional international commercial partnerships during the second half of the year. Pacira expects to report additional data sets during 2027. Cross said the company expects the fourth quarter to be its largest dollar contributor for EXPAREL sales, following historical seasonal patterns. About Pacira BioSciences (NASDAQ:PCRX)Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions.